Business Description
CROSSJECT
ISIN : FR0011716265
Compare
Compare
Traded in other countries / regions
ALCJ.France74C.Germany IPO Date
2014-02-14Description
CROSSJECT manufactures and markets needle-free drug self-injection system.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | -0.12 | |||||
| Debt-to-Equity | -5.83 | |||||
| Debt-to-EBITDA | -2.44 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.04 | |||||
| Beneish M-Score | 3.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6 | |||||
| 3-Year EPS without NRI Growth Rate | 14.3 | |||||
| 3-Year FCF Growth Rate | 8.4 | |||||
| 3-Year Book Growth Rate | -44.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 580.36 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.03 | |||||
| 9-Day RSI | 55.18 | |||||
| 14-Day RSI | 51.58 | |||||
| 6-1 Month Momentum % | 17.04 | |||||
| 12-1 Month Momentum % | -56.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.71 | |||||
| Quick Ratio | 1.24 | |||||
| Cash Ratio | 0.64 | |||||
| Days Inventory | 152.09 | |||||
| Days Sales Outstanding | 9346.52 | |||||
| Days Payable | 181.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.1 | |||||
| Shareholder Yield % | -4.27 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -5501.38 | |||||
| Operating Margin % | -8477.93 | |||||
| Net Margin % | -7226.21 | |||||
| FCF Margin % | -8204.14 | |||||
| ROA % | -32.84 | |||||
| ROIC % | -44.96 | |||||
| ROC (Joel Greenblatt) % | -152.98 | |||||
| ROCE % | -53.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 6.03 | |||||
| PS Ratio | 511.25 | |||||
| EV-to-EBIT | -8.31 | |||||
| EV-to-EBITDA | -11.36 | |||||
| EV-to-Revenue | 771.38 | |||||
| EV-to-FCF | -9.27 | |||||
| Earnings Yield (Greenblatt) % | -12.04 | |||||
| FCF Yield % | -12.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CROSSJECT Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.145 | ||
| EPS (TTM) (€) | -0.26 | ||
| Beta | 0.82 | ||
| Volatility % | 70.93 | ||
| 14-Day RSI | 51.58 | ||
| 14-Day ATR (€) | 0.122761 | ||
| 20-Day SMA (€) | 1.9963 | ||
| 12-1 Month Momentum % | -56.34 | ||
| 52-Week Range (€) | 1.52 - 5.908004 | ||
| Shares Outstanding (Mil) | 45.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CROSSJECT Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CROSSJECT Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
CROSSJECT Frequently Asked Questions
What is CROSSJECT(XPAR:ALCJ)'s stock price today?
The current price of XPAR:ALCJ is €2.08. The 52 week high of XPAR:ALCJ is €5.91 and 52 week low is €1.52.
When is next earnings date of CROSSJECT(XPAR:ALCJ)?
The next earnings date of CROSSJECT(XPAR:ALCJ) is .
Does CROSSJECT(XPAR:ALCJ) pay dividends? If so, how much?
CROSSJECT(XPAR:ALCJ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers